Car T-Cell Therapy

In this video, Saad Usmani, MD, division chief of plasma cell disorders and director of clinical research in hematologic malignancies at Levine Cancer Institute/Atrium Health, offers insights regarding abstracts on developments in chimeric antigen receptor T-cell therapy at ASH Annual Meeting and Expo.

Second-line tisagenlecleucel conferred identical EFS as standard treatment for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, according to randomized phase 3 results presented at ASH Annual Meeting and Exposition.

Minimal residual disease status appeared to influence outcomes after chimeric antigen receptor T-cell therapy for high-risk chronic lymphocytic leukemia, according to study results.

Sixty percent of hematologist-oncologists believe chimeric antigen receptor T-cell therapies provide clinical value at their current price, according to survey results presented at ASH Annual Meeting and Exposition.

Second-line lisocabtagene maraleucel more than quadrupled EFS compared with standard therapy for patients with relapsed or refractory large B-cell lymphoma, according to study results presented at ASH Annual Meeting and Exposition.

Second-line therapy with axicabtagene ciloleucel conferred a fourfold increase in EFS compared with standard-of-care treatment for diffuse large B-cell lymphoma, according to results of a randomized phase 3 study.

Bispecific T-cell engagers have induced impressive response rates among patients with relapsed or refractory multiple myeloma enrolled in early clinical trials.

Tumor gene expression profiles have become standard practice to help guide treatment of several cancer types.

Recent molecular science research may provide important insights as to why chimeric antigen receptor T-cell therapies for solid tumors have failed to achieve results that match those observed in blood cancers.

The FDA granted orphan drug designation to CT120, a novel chimeric antigen receptor T-cell therapy, for the treatment of B-cell acute lymphoblastic leukemia.